Drug Profile
Hydromorphone intrathecal - CNS Therapeutics
Latest Information Update: 08 Oct 2021
Price :
$50
*
At a glance
- Originator CNS Therapeutics
- Developer Piramal Enterprises
- Class Morphine derivatives; Opioid analgesics; Small molecules
- Mechanism of Action Opioid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Pain
Most Recent Events
- 01 Feb 2018 CNS Therapeutics completes a phase III trial in Pain in USA (Intrathecal) (NCT01709721)
- 01 Feb 2018 CNS Therapeutics completes a phase III trial for Pain in USA (Intrathecal) (NCT01709747)
- 20 Mar 2017 Mallinckrodt sold its Intrathecal Therapy Business of drugs for spasticity and pain management to Piramal Enterprises